Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer

NCT04310176 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Ras-mutated Metastatic Colorectal Cancer

Interventions

DRUG: Bevacizumab
DRUG: mFOLFOX6 regimen
DRUG: mOXXEL regimen
DRUG: Valproic acid
DRUG: Capecitabine
DRUG: 5-fluorouracil

Sponsor

National Cancer Institute, Naples